Alborz Darou Pharmaceutical Company
Alborz Darou Pharmaceutical Company is a Tehran Stock Exchange-listed Iranian drug manufacturer, trading as DALBOR. Headquartered in Tehran with a factory in Alborz Industrial Park, Qazvin Province, it produces prescription and over-the-counter medicines, including cardiovascular drugs and Enoxan enoxaparin sodium. It is relevant to pharmaceutical-input suppliers, healthcare buyers and investors tracking domestic medicine manufacturing.
Operations & footprint
Products and services
Alborz Darou Pharmaceutical Company manufactures pharmaceutical products and dosage forms for healthcare, prescription medicine, chronic-disease treatment, and domestic medicine supply chains. Its product profile is linked to Iran’s regulated drug market, raw-material access, pharmaceutical quality requirements, healthcare consumption, and industrial capacity around the Tehran-Karaj pharmaceutical corridor.
Operations and assets
The company operates a pharmaceutical manufacturing factory in Alborz Industrial Park, Qazvin Province, alongside its Tehran head office. Production covers multiple pharmaceutical dosage forms, including cardiovascular medicines and Enoxaparin Sodium under the Enoxan brand.
Geographic footprint
Head office in Tehran; manufacturing factory in Alborz Industrial Park, Qazvin Province, Iran.
Ownership & group structure
Ownership
Parent company: Tedbir Investment Company.
Parent company
Tedbir Investment Company, a subsidiary of Setad (Execution of Imam Khomeini’s Order).
Commercial and investment relevance
In the Hormuz investment graph, Alborz Darou Pharmaceutical Company connects domestic drug manufacturing, healthcare demand, pharmaceutical raw-material imports, regulated pricing, industrial capacity in Alborz, and medicine supply-chain resilience. It is useful for screening healthcare-sector demand, supplier mapping, import-substitution opportunities, and operational risk in pharma manufacturing. Commercial interpretation should verify current product mix, manufacturing licenses, raw-material sourcing, disclosure data, counterparty risk, export activity, and compliance constraints before being treated as actionable intelligence. Alborz Darou is a potential counterparty for pharmaceutical ingredients, excipients, packaging, manufacturing equipment, validation, quality-control and GMP-related services. Its domestic medicine focus links it to procurement and supply-continuity requirements across Iran’s drug-manufacturing chain.
Constraints, risk & compliance
Key risks and constraints
Its manufacturing model depends on continuous access to pharmaceutical inputs and on maintaining GMP-compliant production for a regulated domestic medicines market.
Sanctions and compliance considerations
Its parent-company chain includes Tedbir Investment Company and Setad (Execution of Imam Khomeini’s Order), requiring counterparty-specific sanctions screening before engagement.
Need more than a public profile?
Ask Hormuz to investigate, verify or act locally around Alborz Darou Pharmaceutical Company. Tell us exactly what you need.
Connected Intelligence
Relevant geography, industry, market and execution context for this profile.
Frequently asked questions
Direct answers to the questions most likely to arise when reviewing this profile.
What does Alborz Darou Pharmaceutical Company manufacture?
The company manufactures prescription and over-the-counter medicines in multiple dosage forms, including cardiovascular treatments and Enoxaparin Sodium sold under the Enoxan brand.
Where does Alborz Darou operate?
Alborz Darou has its head office in Tehran and a pharmaceutical factory in Alborz Industrial Park, Qazvin Province, Iran.
Is Alborz Darou a listed company?
Yes. Alborz Darou is listed on the Tehran Stock Exchange under the ticker دالبر (DALBOR).
Who owns Alborz Darou?
Alborz Darou’s parent company is Tedbir Investment Company, which is a subsidiary of Setad (Execution of Imam Khomeini’s Order).